SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla informs about updates

19 Dec 2025 Evaluate

Cipla has informed that Cipla has entered into an exclusive Supply and Marketing Agreement with Pfizer Products India and Pfizer (hereinafter together referred as Pfizer) for marketing and distribution of four brands of Pfizer, Corex, Dolonex, Neksium and Dalacin C for a period of 5 years. The additional details required to be disclosed, pursuant to the Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed as Annexure A. A joint press release issued by Pfizer and Cipla in this regard in enclosed as Annexure B. This intimation is being made to the stock exchanges as part of its commitment to good corporate governance practices.

The above information is a part of company’s filings submitted to BSE.

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×